Midodrine for Symptomatic Orthostatic Hypotension
Primary Indication
Midodrine is indicated for symptomatic neurogenic orthostatic hypotension when non-pharmacologic measures have failed and the patient's quality of life is considerably impaired. 1
The drug should only be continued in patients who report significant symptomatic improvement, as clinical benefits beyond blood pressure elevation (such as improved ability to perform life activities) remain under investigation. 1
Dosing Strategy
Starting and Maintenance Dosing
Start with 10 mg three times daily, with the last dose no later than 6 PM (at least 4 hours before bedtime) to minimize supine hypertension risk. 2, 1
The therapeutic effect peaks at 1 hour post-dose, with standing systolic blood pressure elevated by approximately 15-30 mmHg, and some effect persisting for 2-3 hours. 1
A dose-response study demonstrated that 10 mg is the optimal balance between efficacy and safety, though doses can range from 2.5-30 mg depending on response. 3 The 20 mg dose increased supine systolic pressure ≥200 mmHg in 45% of patients with prolonged elevation lasting 6+ hours. 1
Pharmacokinetics Relevant to Dosing
Midodrine is a prodrug converted to the active metabolite desglymidodrine, which has a half-life of approximately 3-4 hours. 1, 3
Peak blood concentrations of desglymidodrine occur 1-2 hours after dosing, with absolute bioavailability of 93% (unaffected by food). 1
The drug is primarily eliminated renally (80% by active secretion), with renal clearance of approximately 385 mL/minute. 1
Midodrine is removed by dialysis, requiring dose adjustment in hemodialysis patients. 1
Contraindications and Precautions
Absolute Contraindications
Pre-existing sustained supine hypertension above 180/110 mmHg 1
Patients should not take the medication within 4 hours of bedtime due to supine hypertension risk. 2
Major Adverse Effects Requiring Monitoring
Supine hypertension (occurs in up to 25% of patients): Can result in systolic BP >200 mmHg, often lasting 6+ hours. 1, 4 This is the primary dose-limiting factor. 2
Urinary retention: Particularly concerning in patients with prostatic hypertrophy or bladder dysfunction. 2
Scalp tingling and piloerection: Common but generally mild. 2, 4
Pruritus, paresthesias, and chills: Reported frequently but typically well-tolerated. 4
Monitoring Parameters
Blood Pressure Monitoring
Measure both standing and supine blood pressure at baseline and 1 hour post-dose during titration. 1
Standing systolic BP should increase by 15-30 mmHg at 1 hour; if inadequate response, consider dose adjustment. 1
Monitor supine BP to ensure it remains <180/110 mmHg; if elevated, reduce dose or discontinue. 2, 1
Symptom Assessment
Evaluate orthostatic symptoms (dizziness, lightheadedness, syncope) at 1-2 weeks and reassess at 1 and 3 months. 5, 6
Discontinue if no significant symptomatic improvement is reported, as the indication is based on symptom relief, not just BP elevation. 1
Urinary Function
- Monitor for urinary retention, especially in older males or those with known prostatic issues. 2
Treatment Algorithm
First-Line Approach (Before Midodrine)
Acute water ingestion (≥480 mL) for temporary relief: Peak effect at 30 minutes. 2
Physical counter-pressure maneuvers: Leg crossing, squatting, lower body muscle tensing. 2
Compression garments: At least thigh-high, preferably including abdomen. 2
Increased salt (6-9 g/day) and fluid intake: Unless contraindicated by heart failure, renal disease, or hypertension. 2
Pharmacologic Options When Non-Pharmacologic Measures Fail
Midodrine is positioned as a beneficial first-line pharmacologic agent for neurogenic orthostatic hypotension. 2
Alternative Pharmacologic Agents
Droxidopa: Beneficial for neurogenic OH due to Parkinson disease, pure autonomic failure, and multiple system atrophy; may reduce falls. 2 Note that carbidopa may decrease droxidopa effectiveness in Parkinson patients. 2
Fludrocortisone: Increases plasma volume; should be used after other medications when supine hypertension is present. 2 Doses >0.3 mg daily risk adrenal suppression and immunosuppression. 2
Pyridostigmine: Can be used alone or in combination with midodrine. 2 A 2017 study showed midodrine alone was superior to pyridostigmine alone for symptom improvement, though both improved orthostatic BP drop similarly. 6
Atomoxetine: Emerging evidence suggests promise, especially in central autonomic failure, though data are limited. 7
Combination Therapy
Midodrine + pyridostigmine combination showed similar efficacy to midodrine alone for BP improvement but midodrine monotherapy was superior for symptom relief. 6
Combination therapy may be considered in refractory cases, though evidence does not strongly support routine combination use. 6
Clinical Efficacy Evidence
A 2016 Phase 4 tilt-table study demonstrated midodrine significantly increased time to syncopal symptoms (1626.6 seconds vs 1105.6 seconds for placebo, difference 521 seconds, p=0.0131). 8
A 1997 multicenter RCT of 171 patients showed midodrine improved standing systolic BP at all time points (p<0.001), symptoms by week 2 (p=0.001), and global symptom relief scores (p<0.001 by investigator, p=0.03 by patient). 5
Long-term efficacy (up to 3 months) was demonstrated in an 87-patient trial, with sustained improvement in orthostatic BP drop and symptoms. 6
Common Pitfalls to Avoid
Dosing too close to bedtime: Always ensure the last dose is at least 4 hours before lying down to sleep to prevent nocturnal supine hypertension. 2, 1
Failing to monitor supine BP: Supine hypertension is the most serious adverse effect and can be severe (>200 mmHg systolic). 1
Continuing therapy without symptomatic benefit: The FDA approval requires discontinuation if patients do not report significant symptomatic improvement. 1
Ignoring urinary symptoms: Urinary retention can develop insidiously, particularly in vulnerable populations. 2
Using in patients with pre-existing supine hypertension: These patients were routinely excluded from clinical trials and should not receive midodrine. 1